Nohla Therapeutics
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1600 Fairview Ave E Ste 300, Seattle, Wa...Phone Number
(206) 519-5300Website
www.nohlatherapeutics.comRevenue
$42 MillionIndustry
About Nohla Therapeutics
Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla's proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company's lead product candidate, dilanubicel, is currently under evaluation in two ongoing Phase 2 trials. Nohla is also pursuing multiple preclinical and discovery programs in the areas of immune tolerance and other diseases.Explore more
Nohla Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Nohla Therapeutics
Compare insights from companies similar to Nohla Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nohla Therapeutics Tech Stack
A closer look at the technologies used by Nohla Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nohla Therapeutics
Sign Up For FreeTo access detailed company insights
Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla's proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company's lead product candidate, dilanubicel, is currently under evaluation i... Read More
